WallStSmart

Accelerate Diagnostics Inc (AXDX)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 176118% more annual revenue ($20.61B vs $11.70M). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).

AXDX

Avoid

25

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 5.0

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.3
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXDX.

BSXSignificantly Overvalued (-29.4%)

Margin of Safety

-29.4%

Fair Value

$37.35

Current Price

$48.55

$11.20 premium

UndervaluedFair: $37.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXDX0 strengths · Avg: 0/10

No standout strengths identified

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$70.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.588/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

AXDX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$859,9203/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

BSX0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : AXDX

AXDX has a balanced fundamental profile.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : AXDX

The primary concerns for AXDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Key Dynamics to Monitor

AXDX profiles as a value stock while BSX is a mature play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.62 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 25/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accelerate Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Accelerate Diagnostics, Inc., an in vitro diagnostic company, offers solutions for diagnosing serious infections in the United States, Europe, and the Middle East. The company is headquartered in Tucson, Arizona.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?